

Remarks

In the "Notice of Non-Compliant Amendment (37 CFR 1.121)" the Office has noted that claims 33 and 35 should be identified as (Previously presented). By this amendment, the identifiers of claims 33 and 35 have thus been changed. Accordingly, it is submitted that the amendment filed herewith is in full compliance of 37 CFR 1.121.


Conclusions

In view of the above Remarks, it is respectfully submitted that claims 1, 3, 6-9, 11-23, 25-33 and 35 are now in condition for allowance and the early issuance of this case is respectfully requested. In the event the Examiner wishes to contact the undersigned regarding any matter, please call (collect if necessary) the telephone number listed below.

Applicants believe there are no fees due for this Rule 111 Amendment. However, if the Examiner deems that fees are due, please charge these fees to Deposit Account No. **18-1982** for sanofi-aventis U.S. LLC, Bridgewater, NJ. Please credit any overpayment to Deposit Account No. **18-1982**.

Respectfully submitted,

*September 25, 2006*



Balaram Gupta, Ph. D., J. D.  
Registration No. 40,009  
Attorney for Applicants

sanofi-aventis U.S. LLC  
US Patent Operations  
Route #202-206 / P.O. Box 6800  
MAIL CODE: BWD-303A  
Bridgewater, NJ 08807-0800  
Telephone: 908-231-3364  
Telefax: 908-231-2626